Talaris Therapeutics, Inc.

TALS | NASDAQ | 0 Followers

$2.72

-0.73%

-$0.02

Overview Metrics Financials

Company Quality

Profitability Score

9/100

Solvency Score

75/100

Dividends

Dividends data currently unavailable.

Earnings

Earnings data currently unavailable.

My Notes

You haven't added any notes for this stock yet. Use this space to record your insights or strategies.

Profile

Healthcare

Sector

Biotechnology

Industry

Ms. Mary Kay Fenton

CEO

Employees

Louisville

Headquarters

Country

Talaris Therapeutics, Inc. (TALS) is a biotechnology company specializing in the development of therapeutic approaches in the fields of immunology and transplantation. The company focuses on researching and developing drugs with the potential to modulate the immune system and improve outcomes of organ transplantation. Their goal is to reduce the need for long-term immunosuppressive therapy after transplantation and enhance the survival of transplanted organs. Talaris Therapeutics aims to push the boundaries in the treatment of immunological disorders and contribute to advancements in transplantation. Investors interested in innovations in immunology and transplantation therapies might see potential in Talaris Therapeutics, Inc. (TALS) shares for innovation and growth in this field.

Key Metrics TTM

Valuation

Market cap.

$116M

Enterprise Value

$81M

Price to Earnings

-0.77

Price to Sales

0.00

Price to Book

0.25

Price to Cash Flow

-1.40

Profitability

Return on Assets

-31.71%

Return on Equity

-29.43%

Return on Invested Capital

-38.93%

Gross Margin

0.00%

Operating Margin

0.00%

Net Margin

0.00%

Liquidity

Quick Ratio

33.87

Current Ratio

33.87

Cash Ratio

4.64

Inventory Turnover

0.00

Asset Turnover

0.00

Total Liabilities

$7.6M

Solvency

Debt to Assets

0.0007

Debt to Equity

N/A

Interest Coverage

30.66

Equity Ratio

0.97

Long-term Debt to Cap.

0.00

Altman Z-Score

8.16

Performance

Performance data currently unavailable.

Earnings Waterfall

Debt level and coverage

Earnings

Feed

There are no posts to show right now.